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The role of antivirals in patients with acute viral hepatitis B (AVH-B) has not been evaluated
in controlled trials. The aim of this study was to evaluate the efficacy of lamivudine in
patients with AVH-B. AVH-B patients with serum bilirubin of more than 5 mg/dL were
randomized to receive either 100 mg of lamivudine daily for 3 months (group 1, n 31) or
placebo (group 2, n 40). Patients were considered to have severe AVH-B if they fulfilled 2
of 3 criteria: (1) hepatic encephalopathy; (2) serum bilirubin > 10.0 mg/dL; and (3) inter-
national normalized ratio (INR)> 1.6. At week 4, HBV DNA levels were significantly lower
(P  0.037) in group 1 (median: 3.6721 log copies/mL) than group 2 (median: 4.2721 log
copies/mL). Thereafter, HBV DNA levels were comparable in the 2 groups. The improve-
ment in serum bilirubin, ALT, and INR values was similar in the 2 groups. Twenty-two
patients (71%) in group 1 and 25 patients (62.5%) in group 2 had severe AVH-B. Results
were similar when patients with severe AVH-B were analyzed separately. After 12 and 18
months, 93.5% and 92.5%, respectively, of patients in the lamivudine group and 96.7% and
97.5%, respectively, of patients in the placebo group lost HBsAg. There were no deaths in
either group. After 1 year, 21 patients (67.7%) in group 1 and 34 patients (85%) in group 2
developed protective anti-HBs titers (P  0.096). All HBeAg-positive patients in both
groups lost e antigen and anti-HBe developed in 71% and 87.5% of patients in groups 1 and
2, respectively (P  0.132). Conclusion: Though lamivudine causes a greater decrease in
levels of HBV DNA, it does not cause significantly greater biochemical and clinical improve-
ment as compared to placebo in patients with acute hepatitis B. (HEPATOLOGY 2007;45:97-101.)
Acute viral hepatitis B (AVH-B) is successfullycleared in more than 95% of immunocompetentpatients. The remainder of patients may develop
either chronic HBV infection or, in a small proportion,
fulminant hepatitis.
The accepted criteria for defining clinical and serologic
recovery from acute hepatitis B are clearance of circulating
hepatitis B surface antigen (HBsAg) and appearance of
the antibodies to HBsAg (anti-HBs), with normalization
of serum aminotransferases. Nevertheless, a recent long-
term study noted that occult HBV infection might persist
in the liver up to 10 years after clinical resolution.1
Lamivudine is a potent inhibitor of HBV replication that
works by causing chain termination of an RNA-dependent
HBV polymerase.2 It has been administered successfully to
immunocompromised patients with AVH-B.3,4
Since a proportion of patients with AVH-B develop
severe hepatitis and fulminant hepatic failure, a logical
hypothesis is that rapid reduction in theHBVDNA levels
through the use of antiviral agents could result in a less
intense host response against the hepatitis B virus. How-
ever, the experience with lamivudine treatment of immu-
nocompetent patients with AVH-B has been limited to
only a few case reports,5,6 a published abstract of a larger
series7 and a pilot study.8
The aim of this study was to evaluate the efficacy, util-
ity, and safety of lamivudine in treating immunocompe-
tent patients with AVH-B.
Patients and Methods
From January 2002 to March 2005, 138 patients with
acute hepatitis B were seen in the Liver Disease Fol-
low-Up Clinic of G.B. Pant Hospital, New Delhi, India.
Only the 71 patients who fulfilled the inclusion criteria
were enrolled in this study.
Abbreviations: AVH-B, acute viral hepatitis B; HBsAg, hepatitis B surface an-
tigen;
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The diagnosis of acute hepatitis B was based on recent-
onset acute illness including prodromal symptoms, jaun-
dice, and other typical symptoms. Laboratory test results
that supported the diagnosis of acute hepatitis were serum
ALT and serum bilirubin levels at more than 2.5 times the
upper limit and a positive IgM anti-HBc test. Ultrasound
and esophagogastroduodenoscopy were performed to
look for evidence of chronic liver disease. All patients had
normal alpha-fetoprotein levels.
Appropriate serologic tests performed within 7 days of
presentation were used to look for coinfection with hep-
atitis A, hepatitis C, hepatitis D, and hepatitis E, and
HIV.
Patients with coinfection, a history of hepatotoxic drug
intake or alcohol use of more than 20 g/day, or any evi-
dence of past chronic liver disease at presentation or dur-
ing follow-up were excluded. Patients were also excluded
if they had serum bilirubin of less than 5 mg/dL at pre-
sentation.
Patients were classified as having severe AVH-B if they
fulfilled any 2 of 3 criteria:8 (1) hepatic encephalopathy;
(2) serum bilirubin 10.0 mg/dL; and (3) international
normalized ratio (INR) 1.6.
The patients were randomized into 2 groups: group 1,
treatment with 100 mg of lamivudine daily for 3 months;
and group 2, the placebo. Randomization was done with
a random number table. The initial study and random-
ization were planned to enroll 120 patients or continue
the study until 3 years had elapsed, whichever was earlier.
Individual rather than block randomization was done.
The investigators as well as the patients were blinded to
the randomization. The patients in the placebo group
received a placebo pill.
Every week for the first month and then monthly dur-
ing treatment, all patients were monitored for clinical
evidence and grade of hepatic encephalopathy and im-
paired coagulation (abnormal INR) and had their AST/
ALT, serum albumin and bilirubin levels measured. HBV
serology, including serum HBsAg, HBeAg, and anti-
HBe, was checked at baseline and every 3 months. Anti-
HBs titers were checked at 6 and 12 months. A
quantitative HBV DNA assay was performed on days 0
and 4, every week in weeks 1-4, every month for the next
2 months, and then every 3 months for the next 12
months.
All patients were followed for at least 12 months after
the onset of AVH-B. Development of protective anti-
HBs (10 IU/L) was specifically looked for.
Exacerbation of chronic hepatitis B was excluded by
investigating thoroughly for any evidence of chronic liver
disease by ultrasound, upper GI endoscopy, or measuring
for low albumin at presentation. Ultrasound was repeated
at 6 and 12 months, and if there was any suspicion, upper
GI endosopy was also repeated. Liver function tests were
done at every hospital visit.
HBsAg, HBeAg, IgM anti-HBc, anti-HBs, and anti-
HBe were tested by commercially available enzyme-
linked immunoassays. Serum quantitative HBV DNA
assay was performed by use of an ultrasensitive hybrid
capture assay (Digene Labs, Gaithersburg, MD) whose
lower limit of detection is 4,700 copies/mL. An arbitrary
value of 4,700 copies/mL was assigned to values less than
4,700 copies/mL for analysis purposes. In such patients
detection of HBV DNA was done by an in-house quali-
tative PCR test to indicate whether the patient was nega-
tive or positive for viral DNA. The lower limit of
detection was 600 copies/mL.9,10
Statistics. Statistical analysis was performed by stan-
dard methods. Continuous variables were analyzed using
the independent Student t test. Fischer’s exact test and the
chi-square test were used to analyze categorical data. A P
value of less than 0.05 was considered statistically signif-
icant. All the statistical calculations were done using SPSS
10.05 software.
Results
Thirty-one patients were in the lamivudine group and
40 patients in the placebo group. Both groups were com-
parable in age, sex distribution, interval from onset of
jaundice to start of therapy, and serum bilirubin, ALT,
INR, and HBVDNA levels at the start of therapy. Twen-
ty-two patients (71%) in the lamivudine group and 25
patients (62.5%) in the placebo group had severe AVH-B.
Two patients (6.5%) in the lamivudine group and 1 pa-
tient (2.5%) in the placebo group presented with hepatic
encephalopathy. The baseline characteristics of the pa-
tients are shown in Table 1.
All patients were HBsAg positive at presentation: 60
(84.5%) were HBeAg positive (26 [83.9%] in the lami-
vudine group and 34 [85%] in the placebo group) and
11(15.5%)were serumHBeAg negative (5 [16.1%] in the
lamivudine group and 6 [15%] in the placebo group); all
patients were serum IgM anti-HBc positive. None of the
patients was anti-HBe positive at presentation.
Mean  SD and median (range) log copies of serum
HBV DNA were comparable (P 0.657) in severe cases
(5.4081  1.0277; 5.1280 [4.01-8.60]) and nonsevere
cases (5.2925 1.0424;5.1114 [4.0-8.46]).
Virological Follow-Up of Patients. Figure 1 shows
the median and interquartile HBV DNA levels in both
groups of patients. At week 4, HBV DNA levels were
significantly lower (P 0.037) in the lamivudine-treated
group (median: 3.6721 log copies/mL) than in the
placebo-treated group (median: 4.2721 log copies/mL).
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Thereafter, there was no difference in HBV DNA levels
between the 2 groups of patients. Figure 2 shows the
proportion of patients who were HBVDNA positive
(600 copies/mL) in both groups. All patients wereHBV
DNA positive (100%) at the start, and this decreased to
about 20% in both the lamivudine and placebo groups
after 1year.
After 1 year, 29 patients (93.5%) in the lamivudine
group and 37 patients (92.5%) in the placebo group lost
HBsAg. After 18 months, 30 patients (96.7%) in the
lamivudine group and 39 patients (97.5%) in the placebo
group lost HBsAg.
Follow-up of patients who were still HBsAg positive
after 1 year is depicted in Table 2. The 2 patients (one
from each group) who were still HBsAg positive after 18
months developed chronic hepatitis B. Both underwent
liver biopsy, which showed no fibrosis and only minimal
inflammation. The lamivudine-treated patient had F0 fi-
brosis and a hepatic activity index (HAI) of 1. The place-
bo-treated patient had F0 fibrosis and an HAI of 2.
All the patients who were HBeAg positive (26 in the
lamivudine group and 34 in the placebo group) became
HBeAg negative. Overall, anti-HBe developed in 22 of 31
Table 1. Baseline Characteristics of Patients
Characteristic Lamivudine (n  31) Placebo (n  40) P
Age (years) 0.820
Mean  SD 37.2 15.9 36.4 13.3
Median (range) 35(12-78) 36(10-70)
Male sex, N (%) 20 (64.5) 32 (80) 0.181
Severe hepatitis N(%) 22 (71) 25 (62.5) 0.614
Hepatic encephalopathy at start of therapy [n (%)]
Grade 0 0 0 0.577
Grade1 0 0
Grade2 0 0
Grade3 2 (6.5) 1 (2.5)
Grade4 0 0
Interval from onset to start of therapy (days)
Mean  SD 18.2 9.2 14.6 7.6 0.067
Median (range) 20.0 (6.0-45) 14.0 (2-40)
Bilirubin at start of therapy (mg/dL)
Mean  SD 10.9 5.7 12.3 6.7 0.365
Median (range) 10.3(5.0-27) 10.5(5.0-27)
ALT at start of therapy (IU/L)
Mean  SD 1658.6 1309.6 1253.4 1004.2 0.144
Median (range) 1250.0 (211-6400) 886.0 (124-3697)
INR at start of therapy
Mean  SD 2.0 0.86 1.89 0.41 0.434
Median (range) 1.68 (1.6-4.5) 1.74 (1.55-3.24)
HBeAg positive [n (%)] 26 (83.9) 34 (85) 1.00
IgM-anti-HBc positive [n (%)] 31 (100) 40 (100) 1.00
Detectable HBV DNA (4,700 copies/mL) [n (%)] 31 (100) 40 (100) 1.00
HBV DNA at start of therapy (log copies/mL)
Mean  SD 5.531 1.133 5.243 0.932 0.245
Median (range) 5.135 (4.16-8.6) 5.085 (4.0-8.48)
Fig. 1. Median and interquartile HBV DNA levels in both groups of
patients during the course of treatment and during follow-up.
Fig. 2. Proportion of patients who were HBVDNA positive (600
copies/mL) at various time points in both groups.
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patients (71%) in the lamivudine group and 35 of 40
patients (87.5%) in the placebo group (P  0.132).
There was a slightly lower rate of development of pro-
tective anti-HBs in patients treated with lamivudine. Af-
ter 1 year, 21 patients (67.7%) in the lamivudine group
and 34 patients (85%) in the placebo group developed
protective anti-HBs titers. However, the difference be-
tween the 2 groups was not significant (P  0.096).
Among the patients with severe disease, 16 (72.2%) in the
lamivudine group and 21 (84.0%) in the placebo group
(P  0.346) developed protective anti-HBs titers.
Biochemical Follow-Up of Patients. Figure 3 shows
median and interquartile bilirubin levels in both groups of
patients. There was no significant difference between the
lamivudine-treated and placebo-treated patients. Among
the severe cases also, the results were similar.
Figure 4 shows the median and interquartile ALT lev-
els in both group of patients. There was no significant
difference between the lamivudine-treated and the place-
bo-treated patients. The results were also similar among
those with severe disease.
Similarly, there was no significant difference between
groups in trends of INR improvement.
Clinical Outcomes of Patients. There was no mor-
tality in either group. All the patients presenting with
encephalopathy recovered within 1 week. There was also
no significant difference in the clinical outcome between
the lamivudine-treated and the placebo-treated groups.
Safety. No patient had a serious adverse event that
could be attributed to lamivudine, and all patients toler-
ated therapy without dose modification or the need for
early discontinuation. No patient developed pancreatitis,
neuropathy, or renal impairment.
Discussion
This is the first randomized trial that has compared the
use of lamivudine with placebo for the treatment of acute
hepatitis B. In this study, we administered 100 mg of lami-
vudine daily over a short period (3 months) to patients with
acute hepatitis B infection. The results showed that though
lamivudine therapy in AVH-B causes a greater decrease in
HBV DNA levels, the clinical benefit in biochemical and
clinical improvement is modest even in severe cases.
Patients with acuteHBV infection can develop chronic
HBV infection or fulminant hepatitis (0.5%-2%).1 Lami-
vudine has been administered successfully to immuno-
compromised patients and to liver transplant recipients
with AVH-B.3,4 The experience with lamivudine treat-
ment of immunocompetent patients with AVH-B is lim-
ited. In a small study, 3 patients with acute hepatitis B
were treated with lamivudine 150 mg daily. In all the
patients, serum HBV DNA became undetectable, and
HBsAg and HBeAg disappeared.6
Table 2. Follow-Up of Patients Who Were HBsAg-Positive After 12 Months
Patient
Number Group
12 Months 18 Months
HBsAg
HBV DNA (log
cp/mL)
ALT
(IU/L) HBsAg
HBV DNA (log
cp/mL)
ALT
(IU/L)
1 Lam  4.09 51  600 copies/mL 35
2* Lam  4.38 50  4.1 49
3* Placebo  4.82 48  4.08 59
4 Placebo  4.36 52  600 copies/mL 32
5 Placebo  600 copies/mL 40  600 copies/mL 30
*These 2 patients developed chronic hepatitis B.
Fig. 3. Median and interquartile bilirubin levels in both groups of
patients.
Fig. 4. Median and interquartile ALT levels in both groups of pa-
tients.
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In a case report, a 74-year-old patient with acute hep-
atitis B and hepatic encephalopathy responded to lamivu-
dine with the disappearance of serum HBsAg.5
In a study of 46 patients with severe acute hepatitis B
(the criteria for severity were unclear), 3 months after
lamivudine treatment, serum HBV DNA became unde-
tectable in all the patients, and anti-HBe became positive
in 87.5% of the patients.7
In another study, 15 patients with severe acute HBV
infection were treated with lamivudine 100 mg daily for
3-6 months, with 5 patients having grade 1-4 encepha-
lopathy prior to onset of treatment. Thirteen (86.6%)
patients responded. Encephalopathy disappeared within
3 days of treatment. SerumHBVDNA became undetect-
able (by PCR) within 4 weeks, and liver enzymes normal-
ized within 8 weeks. Anti-HBe developed in 9 of 11
HBeAg-positive patients within 12 weeks.8
Long-term lamivudine treatment is associated with the
emergence of lamivudine-resistant mutants. However,
lamivudine resistance rarely occurs during the first 36
weeks of therapy.11 We administered lamivudine for only
12 weeks, thereby attempting to prevent the emergence of
lamivudine resistance.
Although HBV DNA levels fell more rapidly in the
patients who received lamivudine, there were no differ-
ences in the clinical course and outcome between the 2
treatment groups. Clinical recovery was no faster in the
lamivudine-treated than in the placebo-treated patients.
More potent antiviral drugs such as entecavir and te-
nofovir are now available. It is possible that these antivi-
rals may be useful in a select group of patients with severe
acute hepatitis B. It could be advocated that patients with
signs of fulminant hepatitis in centers with liver trans-
plant facilities should be treated with potent antiviral
drugs, as these patients might go to transplantation and it
would be best to have HBVDNA levels as low as possible
at the time of transplant. However, it would be worth-
while to measure HBV DNA levels in patients with such
severe or fulminant hepatitis B, as their HBV DNA levels
are likely to be low or undetectable.12
There is no clear explanation of why, despite a greater
decrease inHBVDNA levels in the lamivudine group, the
clinical benefits of biochemical and clinical improvement
were unimpressive. The resolution of acute hepatitis B
involves a complex interplay of innate and adaptive im-
mune responses and cellular and humoral immunity. It is
believed that HBV is a noncytopathic virus and that cy-
totoxic T lymphocytes mediate clearance of HBV-in-
fected cells through a cytolytic process.13,14 Therefore, as
the injury during acute hepatitis B is mainly noncytolytic
with some contribution from cytolytic mechanisms and
HBV is primarily a noncytopathic virus, the decline in
HBV DNA by lamivudine is not accompanied by a com-
mensurate decline in serum bilirubin and ALT values.
In conclusion, although lamivudine caused a greater
decrease in HBV DNA levels in patients with acute hep-
atitis B, it did not produce significant biochemical and
clinical improvement compared to that in patients who
received the placebo.
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